Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses

Kenji Kanayama, Kazuhiko Nakamura, Haruei Ogino, Yorinobu Sumida, Eikichi Ihara, Hirotada Akiho, Ryoichi Takayanagi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background Treatment with infliximab, a chimeric antitumor necrosis factor (TNF)-α antibody, is highly efficient in patients with inflammatory bowel disease (IBD). It neutralizes soluble TNF-α and induces the apoptosis of transmembrane TNF-α-positive macrophages and T cells in the gut. Recently, T helper (Th)17, as well as Th1, responses have been implicated in the pathogenesis of IBD. Aims To clarify the effects of infliximab on Th1 and Th17 responses in vitro. Methods Naive CD4 + T cells isolated from the peripheral blood of healthy volunteers were stimulated under Th1- or Th17-inducing conditions in the presence of 10 μg/ml of infliximab or control immunoglobulin (Ig)G1. The concentrations of interferon (IFN)-c, interleukin (IL)-17, and TNF-α in the culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA). Th1 and Th17 cells were immunostained with infliximab or control IgG1 and transmembrane TNF-α-positive cells were analyzed by flow cytometry. Annexin V staining and terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assays were conducted in order to analyze the percentage of apoptotic cells. Results Both Th1 and Th17 cells expressed soluble and transmembrane TNF-α abundantly. Although infliximab suppressed IFN-γ secretion by Th1 cells and IL-17 secretion by Th17 cells, the level of the former was more profound than the latter. Infliximab increased annexin V- and TUNEL-positive apoptotic cells under Th1-inducing conditions, but not under Th17-inducing conditions. Conclusions Infliximab suppressed Th1 and Th17 differentiation in vitro; however, IFN-γ production by Th1 cells was more profoundly suppressed than IL-17 secretion by Th17 cells. Th1 responses were more susceptible to infliximab-mediated apoptosis than Th17 responses. Our results clarify a new mechanism of action of infliximab.

Original languageEnglish
Pages (from-to)3525-3533
Number of pages9
JournalDigestive Diseases and Sciences
Volume56
Issue number12
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Immunosuppression
Th1 Cells
Th17 Cells
Interleukin-17
Interferons
Annexin A5
Inflammatory Bowel Diseases
Apoptosis
T-Lymphocytes
Infliximab
DNA Nucleotidylexotransferase
Immunoglobulins
Healthy Volunteers
Flow Cytometry
Necrosis
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Macrophages
Staining and Labeling
Antibodies

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses. / Kanayama, Kenji; Nakamura, Kazuhiko; Ogino, Haruei; Sumida, Yorinobu; Ihara, Eikichi; Akiho, Hirotada; Takayanagi, Ryoichi.

In: Digestive Diseases and Sciences, Vol. 56, No. 12, 01.12.2011, p. 3525-3533.

Research output: Contribution to journalReview article

Kanayama, Kenji ; Nakamura, Kazuhiko ; Ogino, Haruei ; Sumida, Yorinobu ; Ihara, Eikichi ; Akiho, Hirotada ; Takayanagi, Ryoichi. / Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 12. pp. 3525-3533.
@article{f31c1323616e40b0aa63679923b8f41e,
title = "Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses",
abstract = "Background Treatment with infliximab, a chimeric antitumor necrosis factor (TNF)-α antibody, is highly efficient in patients with inflammatory bowel disease (IBD). It neutralizes soluble TNF-α and induces the apoptosis of transmembrane TNF-α-positive macrophages and T cells in the gut. Recently, T helper (Th)17, as well as Th1, responses have been implicated in the pathogenesis of IBD. Aims To clarify the effects of infliximab on Th1 and Th17 responses in vitro. Methods Naive CD4 + T cells isolated from the peripheral blood of healthy volunteers were stimulated under Th1- or Th17-inducing conditions in the presence of 10 μg/ml of infliximab or control immunoglobulin (Ig)G1. The concentrations of interferon (IFN)-c, interleukin (IL)-17, and TNF-α in the culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA). Th1 and Th17 cells were immunostained with infliximab or control IgG1 and transmembrane TNF-α-positive cells were analyzed by flow cytometry. Annexin V staining and terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assays were conducted in order to analyze the percentage of apoptotic cells. Results Both Th1 and Th17 cells expressed soluble and transmembrane TNF-α abundantly. Although infliximab suppressed IFN-γ secretion by Th1 cells and IL-17 secretion by Th17 cells, the level of the former was more profound than the latter. Infliximab increased annexin V- and TUNEL-positive apoptotic cells under Th1-inducing conditions, but not under Th17-inducing conditions. Conclusions Infliximab suppressed Th1 and Th17 differentiation in vitro; however, IFN-γ production by Th1 cells was more profoundly suppressed than IL-17 secretion by Th17 cells. Th1 responses were more susceptible to infliximab-mediated apoptosis than Th17 responses. Our results clarify a new mechanism of action of infliximab.",
author = "Kenji Kanayama and Kazuhiko Nakamura and Haruei Ogino and Yorinobu Sumida and Eikichi Ihara and Hirotada Akiho and Ryoichi Takayanagi",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s10620-011-1780-1",
language = "English",
volume = "56",
pages = "3525--3533",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses

AU - Kanayama, Kenji

AU - Nakamura, Kazuhiko

AU - Ogino, Haruei

AU - Sumida, Yorinobu

AU - Ihara, Eikichi

AU - Akiho, Hirotada

AU - Takayanagi, Ryoichi

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background Treatment with infliximab, a chimeric antitumor necrosis factor (TNF)-α antibody, is highly efficient in patients with inflammatory bowel disease (IBD). It neutralizes soluble TNF-α and induces the apoptosis of transmembrane TNF-α-positive macrophages and T cells in the gut. Recently, T helper (Th)17, as well as Th1, responses have been implicated in the pathogenesis of IBD. Aims To clarify the effects of infliximab on Th1 and Th17 responses in vitro. Methods Naive CD4 + T cells isolated from the peripheral blood of healthy volunteers were stimulated under Th1- or Th17-inducing conditions in the presence of 10 μg/ml of infliximab or control immunoglobulin (Ig)G1. The concentrations of interferon (IFN)-c, interleukin (IL)-17, and TNF-α in the culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA). Th1 and Th17 cells were immunostained with infliximab or control IgG1 and transmembrane TNF-α-positive cells were analyzed by flow cytometry. Annexin V staining and terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assays were conducted in order to analyze the percentage of apoptotic cells. Results Both Th1 and Th17 cells expressed soluble and transmembrane TNF-α abundantly. Although infliximab suppressed IFN-γ secretion by Th1 cells and IL-17 secretion by Th17 cells, the level of the former was more profound than the latter. Infliximab increased annexin V- and TUNEL-positive apoptotic cells under Th1-inducing conditions, but not under Th17-inducing conditions. Conclusions Infliximab suppressed Th1 and Th17 differentiation in vitro; however, IFN-γ production by Th1 cells was more profoundly suppressed than IL-17 secretion by Th17 cells. Th1 responses were more susceptible to infliximab-mediated apoptosis than Th17 responses. Our results clarify a new mechanism of action of infliximab.

AB - Background Treatment with infliximab, a chimeric antitumor necrosis factor (TNF)-α antibody, is highly efficient in patients with inflammatory bowel disease (IBD). It neutralizes soluble TNF-α and induces the apoptosis of transmembrane TNF-α-positive macrophages and T cells in the gut. Recently, T helper (Th)17, as well as Th1, responses have been implicated in the pathogenesis of IBD. Aims To clarify the effects of infliximab on Th1 and Th17 responses in vitro. Methods Naive CD4 + T cells isolated from the peripheral blood of healthy volunteers were stimulated under Th1- or Th17-inducing conditions in the presence of 10 μg/ml of infliximab or control immunoglobulin (Ig)G1. The concentrations of interferon (IFN)-c, interleukin (IL)-17, and TNF-α in the culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA). Th1 and Th17 cells were immunostained with infliximab or control IgG1 and transmembrane TNF-α-positive cells were analyzed by flow cytometry. Annexin V staining and terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) assays were conducted in order to analyze the percentage of apoptotic cells. Results Both Th1 and Th17 cells expressed soluble and transmembrane TNF-α abundantly. Although infliximab suppressed IFN-γ secretion by Th1 cells and IL-17 secretion by Th17 cells, the level of the former was more profound than the latter. Infliximab increased annexin V- and TUNEL-positive apoptotic cells under Th1-inducing conditions, but not under Th17-inducing conditions. Conclusions Infliximab suppressed Th1 and Th17 differentiation in vitro; however, IFN-γ production by Th1 cells was more profoundly suppressed than IL-17 secretion by Th17 cells. Th1 responses were more susceptible to infliximab-mediated apoptosis than Th17 responses. Our results clarify a new mechanism of action of infliximab.

UR - http://www.scopus.com/inward/record.url?scp=84856179279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856179279&partnerID=8YFLogxK

U2 - 10.1007/s10620-011-1780-1

DO - 10.1007/s10620-011-1780-1

M3 - Review article

C2 - 21678051

AN - SCOPUS:84856179279

VL - 56

SP - 3525

EP - 3533

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 12

ER -